Approval for addition of the architect free psa to the i2000sr platform, a member of the architect i2000 instrument family.  The device, as modified, will be marketed under the trade name architect free psa and is indicated for the quantitative determination of free prostate specific antigen (psa) in human serum.  The architect free psa is intended to be used in conjunction with the architect total psa assay in men aged 50 years or older with total psa values between 4 and 10 ng/ml and dre non-suspicious for cancer to determine the % free psa value.  The architect % free psa value can be used as an aid in discriminating between prostate cancer and benign disease.